Tyme Technologies — Investor Presentation (November 2017)
22 slides from Tyme Technologies's investor presentation, Nov 13, 2017
Slide 1: Tyme: the Future of Cancer Treatments
Exhibit 99.1 TYME: the FUTURE of CANCER TREATMENTS NOVEMBER 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation and associated oral statements are "forward-looking statements" under the Private Securities Litigation Reform Act. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risk fac
Slide 3: SM-88 Rationale and Mechanism of Action
SM-88 Rationale and Mechanism of Action Tumors require excess nutrients including glucose, amino acids and lipids to support rapid replication Cancer cells utilize unique metabolic mechanisms to obtain the nutrients they require for growth Nearly all cancers use aerobic glycolysis (Warburg Effect) r
Slide 4: Tumor Metabolism - Unique Nutritional Needs
Tumor Metabolism- Unique Nutritional Needs Cancer requires the accumulation of significant biomass to support rapid proliferation. (Science 2009) Amino acids and lipids make up a substantial portion of the nutrients to support this growth (Dev Cell 2016, Clin Cancer Res 2015) Cancer cells upregulate
Slide 5: Tumor Physiology - Managing Hostile Environment
Nath S, Roy LD, Grover P, Rao S, Mukherjee P Pancreas (2015) and S Nath et.al. tTrends in Molecular Medicine 2014 Tumor Physiology- Managing Hostile Environment Cancer’s inefficient metabolism (Warburg Effect/ aerobic glycolysis) results in an elevated level of intracellular reactive oxygen species
Slide 6: Breaking the Metabolic Circuit of Cancer
Breaking the Metabolic Circuit of Cancer 3) Protective Mucin Layer Compromised 4) Cell Death From Oxidative Stress Immune Response Free Radicals (ROS) 2) Protein Synthesis Fails 1) Induce Uptake of Tyme’s Dysfunctional Tyrosine
Slide 7: Components - Rationale
SM-88 Components- Rationale Tyme approach employs multiple mechanisms intended to optimally target a key cellular process. We believe such an approach is critical in addressing the complex nature of cancer. In combination with a proprietary tyrosine agent, SM-88 leverages well documented properties
Slide 8: Components - Tyrosine Derivative
SM-88 Components- Tyrosine Derivative Bottom Line: Introduce a non-functional protein building block to primarily disrupt the production/fidelity of cancer cell’s mucin. The core component of SM-88 is a modified form of the non-essential amino acid tyrosine. This agent is a racemic mix of D-/L-isome
Slide 9: Components - Rapamycin
SM-88 Components- Rapamycin Bottom Line: Rapamycin is used to enhance uptake of Tyme’s tyrosine derivative Rapamycin (sirolimus) is a mTOR (mammalian target of rapamycin) inhibitor originally approved for the treatment of transplant rejection (Rapamune PI). Nearly all eukaryotic cells express mTOR w
Slide 10: Components - Phenytoin
SM-88 Components- Phenytoin Bottom Line: Increased reactive lipid species in the tumor microenvironment to enhance the redox potential of the cancer cell. Phenytoin was originally approved for the treatment of certain forms of epilepsy (FDA label). The drug is recognized as an inducer of certain P45
Slide 11: Components - Methoxsalen
SM-88 Components- Methoxsalen Bottom Line: Increased melanin and reactive oxygen species and serve as a catalyst for oxidative reactions. Methoxsalen (Oxsoralen) was originally approved for the treatment of severe psoriasis in conjunction with UVA treatment (FDA label). The daily dosing for an avera
Slide 12: Profile: Efficacy Summary
SM-88 Profile: Efficacy Summary First Human Study Monotherapy efficacy in patients with actively progressive disease Survival with SD Post SM-88 therapy did not improve survival Compassionate use Program All patients had progressive disease upon entry Tumor responses observed in a range of solid and
Slide 13: Profile: Safety Summary
SM-88 Profile: Safety Summary No drug-related serious adverse events (SAEs) observed with SM-88 in over 100 metastatic patients treated Only manageable grade 1/2 events observed Safety profile confirmed in Phase 2 prostate patients Improvement in performance The First Human Study was designed primar
Slide 14: Summary
SM-88 Summary SM-88‘s design was based on well documented biologic principles of cancer biology and physiology Selection of components that could work together to drive ROS-driven apoptosis of the cancer cell Efficacy of SM-88 parallels the presence of the Warburg Effect and associated biology acros
Slide 15: Relevant Literature: Warburg Effect and Tumor Metabolism
Relevant Literature Warburg Effect and Tumor Metabolism Molecular Pathways: Trafficking of Metabolic Resources in the Tumor Microenvironment Clinical Cancer Research (2015) vol 21, is. 4 The Warburg effect and drug resistance. British Journal of Pharmacology 2015;173 Cancer Cell Metabolism: Warburg
Slide 16: Relevant Literature, Continued: Mucin Role in Cancer Survival
Relevant Literature, Continued Mucin Role in Cancer Survival Molecular Pathways: Trafficking of Metabolic Resources in the Tumor Microenvironment Clinical Cancer Research (2015) vol 21, is. 4 Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone. Blood; 93: No 4 M
Slide 17: Relevant Literature, Continued: Amino Acid Uptake by Cancer Cells
Relevant Literature, Continued Amino Acid Uptake by Cancer Cells Nonessential amino acid metabolism in breast cancer – Adv Biological Regulation. 2016;62 Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells. ScienceDirect Tumor microenvironment deriv
Slide 18: Relevant Literature, Continued: Cellular Processing of D-Amino Acids
Relevant Literature, Continued Cellular Processing of D-Amino Acids The ribosome can discriminate the chirality of amino acids within its peptidyl-transferase center. PNAS 2015;112:19 Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping. Nature Reviews Cancer 2011; 11 Kinetics of Rib
Slide 19: Relevant Literature, Continued: Rapamycin and Cancer Cell Metabolism
Relevant Literature, Continued Rapamycin and Cancer Cell Metabolism Molecular Pathways: Trafficking of Metabolic Resources in the Tumor Microenvironment Clinical Cancer Research (2015) vol 21, is. 4 mTOR Signaling at a Glance. Journal of Cell Science 2009; 122:20 Expression of cancer type amino acid
Slide 20: Relevant Literature, Continued: Phenytoin and Role of Lipids
Relevant Literature, Continued Phenytoin and Role of Lipids in Cancer Metabolism The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and metastasis. Molecular Cancer. 2015;14:13 Decreased total antioxidant capacity and elevated lipid hydroperoxide concentrations in
Slide 21: Relevant Literature, Continued: Methoxsalen and Melanocytes
Relevant Literature, Continued Methoxsalen and Melanocytes and Role of Lipids in Cancer Metabolism Melanocytes as Instigators and Victims of Oxidative Stress – J Inv Dermatology 2014 What are melanocytes really doing all day long…? : from the ViewPoint of a keratinocyte: Melanocytes – cells with a s
Slide 22: Contact Information
44 WALL STREET 12TH FLOOR NEW YORK, NY 10005 NASDAQ: TYME [email protected] TYMEINC.COM
Tyme Technologies — Investor Presentation (November 2017) on 6ix